Shares of chip makers such as Nvidia and solar stocks rise after the Federal Reserve slashes interest rates, Intel says it has no plans to sell its majority stake in Mobileye, and Progyny sinks after a ‘significant’ client plans to terminate a services agreement.

Vivos Therapeutics shares surged 47.50% to close at $4.13, after hitting an intraday high of $5.95 and a low of $3.02. The stock’s 52-week high is $48.79, and its 52-week low is $1.91. The FDA granted 510 (k) clearance to the company’s flagship oral medical device, poised to disrupt the pediatric sleep apnea market.